Screener
Intellia Therapeutics NTLA Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$106.63M-5.3% | -$96.23M+15.8% | -$95.79M+25.7% | -$101.32M+25.3% | -$101.26M+31.1% | ||
| $2.1M-16.0% | $2.2M-11.8% | $2.38M-7.2% | $2.4M-7.7% | $2.5M-3.8% | ||
| $18.08M-18.0% | $13.48M-38.3% | $16.74M-57.7% | $19.6M-50.5% | $22.04M-46.1% | ||
| -$83.11M+16.6% | -$117.35M+21.2% | -$69.29M+18.7% | -$76.9M+9.4% | -$99.62M-71.2% | ||
| $1.81M+657% | $79K-89.3% | $126K-87.2% | $29K-97.7% | $239K-76.4% | ||
| -$141.57M-232% | $66.31M-29.7% | $27.53M-81.8% | $0+100% | $106.91M+542% | ||
| $196.12M+1,238% | $33.57M— | $1.98M-14.7% | $114.86M+39.7% | $14.65M-64.5% | ||
| -$28.57M— | -$17.47M+68.0% | -$39.77M— | $37.22M+459% | —— | ||
| -$84.92M+15.0% | -$117.43M+21.5% | -$69.41M+19.5% | -$76.93M+10.7% | -$99.86M-68.7% |
FAQ
- How much cash does Intellia Therapeutics generate?
- Intellia Therapeutics (NTLA) generated -$346.6M in operating cash flow over the trailing twelve months.
- What is Intellia Therapeutics's free cash flow?
- After $2.0M of capital expenditures, Intellia Therapeutics's free cash flow was -$348.7M over the trailing twelve months, up 17.3% year over year.
- Where does Intellia Therapeutics's cash flow data come from?
- Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
